• 1
    Jemal A,Siegel R,Ward E,Hao Y,Xu J,Murray T,Thun MJ. Cancer Stat, 2008. CA Cancer J Clin 2008; 58: 7196.
  • 2
    Walsh PC,DeWeese TL,Eisenberger MA. Clinical practice. Localized prostate cancer. N Engl J Med 2007; 357: 2696705.
  • 3
    Pound CR,Partin AW,Eisenberger MA,Chan DW,Pearson JD,Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 15917.
  • 4
    Simmons MN,Stephenson AJ,Klein EA. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol 2007; 51: 117584.
  • 5
    Chun FK,Karakiewicz PI,Briganti A,Gallina A,Kattan MW,Montorsi F,Huland H,Graefen M. Prostate cancer nomograms: an update. Eur Urol 2006; 50: 91426, discussion 26.
  • 6
    Stephenson AJ,Scardino PT,Eastham JA,Bianco FJ,Jr,Dotan ZA,Fearn PA,Kattan MW. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006; 98: 7157.
  • 7
    Haese A,Chaudhari M,Miller MC,Epstein JI,Huland H,Palisaar J,Graefen M,Hammerer P,Poole EC,O'Dowd GJ,Partin AW,Veltri RW. Quantitative biopsy pathology for the prediction of pathologically organ-confined prostate carcinoma: a multiinstitutional validation study. Cancer 2003; 97: 96978.
  • 8
    Williams SG,Buyyounouski MK,Pickles T,Kestin L,Martinez A,Hanlon AL,Duchesne GM. Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: statistical significance without predictive performance. Int J Radiat Oncol Biol Phys 2008; 70: 116975.
  • 9
    Algaba F,Arce Y,Oliver A,Barandica C,Santaularia JM,Montanes R. Prognostic parameters other than Gleason score for the daily evaluation of prostate cancer in needle biopsy. Eur Urol 2005; 48: 56671.
  • 10
    Freedland SJ,Csathy GS,Dorey F,Aronson WJ. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol 2002; 167: 51620.
  • 11
    Albertsen P. Predicting survival for men with clinically localized prostate cancer: what do we need in contemporary practice? Cancer 2008; 112: 13.
  • 12
    O'Donnell H,Parker C. What is low-risk prostate cancer and what is its natural history? World J Urol 2008; 26: 41522.
  • 13
    D'Amico AV,Chen MH,Roehl KA,Catalona WJ. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol 2005; 23: 49759.
  • 14
    Rhodes DR,Sanda MG,Otte AP,Chinnaiyan AM,Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 2003; 95: 6618.
  • 15
    Pollack A,Cowen D,Troncoso P,Zagars GK,von Eschenbach AC,Meistrich ML,McDonnell T. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Cancer 2003; 97: 16308.
  • 16
    Rubio J,Ramos D,Lopez-Guerrero JA,Iborra I,Collado A,Solsona E,Almenar S,Llombart-Bosch A. Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur Urol 2005; 48: 74551.
  • 17
    Oxley JD,Winkler MH,Parry K,Brewster S,Abbott C,Gillatt DA. p53 and bcl-2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy. BJU Int 2002; 89: 2732.
  • 18
    Bubendorf L,Tapia C,Gasser TC,Casella R,Grunder B,Moch H,Mihatsch MJ,Sauter G. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol 1998; 29: 94954.
  • 19
    Sebo TJ,Cheville JC,Riehle DL,Lohse CM,Pankratz VS,Myers RP,Blute ML,Zincke H. Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer. Am J Surg Pathol 2002; 26: 4319.
  • 20
    International Union Against Cancer: Classification of malignant tumors, 6 edn. New York: Wiley Liss, 2002.
  • 21
    van der Kwast TH,Lopes C,Santonja C,Pihl CG,Neetens I,Martikainen P,Di Lollo S,Bubendorf L,Hoedemaeker RF. Guidelines for processing and reporting of prostatic needle biopsies. J Clin Pathol 2003; 56: 33640.
  • 22
    Bubendorf L,Sauter G,Moch H,Schmid HP,Gasser TC,Jordan P,Mihatsch MJ. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996; 178: 43741.
  • 23
    Zellweger T,Ninck C,Mirlacher M,Annefeld M,Glass AG,Gasser TC,Mihatsch MJ,Gelmann EP,Bubendorf L. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate 2003; 55: 209.
  • 24
    Bubendorf L,Sauter G,Moch H,Jordan P,Blochlinger A,Gasser TC,Mihatsch MJ. Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol 1996; 148: 155765.
  • 25
    Dall'Era MA,Cooperberg MR,Chan JM,Davies BJ,Albertsen PC,Klotz LH,Warlick CA,Holmberg L,Bailey DE,Jr,Wallace ME,Kantoff PW,Carroll PR. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 2008; 112: 16509.
  • 26
    Srigley JR,Amin MB,Epstein JI,Grignon DJ,Humphrey PA,Renshaw AA,Wheeler TM. Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland. Arch Pathol Lab Med 2006; 130: 93646.
  • 27
    Briganti A,Chun FK,Hutterer GC,Gallina A,Shariat SF,Salonia A,Scattoni V,Valiquette L,Montorsi F,Rigatti P,Graefen M,Huland H, et al. Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. Eur Urol 2007; 52: 73343.
  • 28
    Egevad L,Allsbrook WC,Jr,Epstein JI. Current practice of diagnosis and reporting of prostate cancer on needle biopsy among genitourinary pathologists. Hum Pathol 2006; 37: 2927.
  • 29
    Fitzsimons NJ,Presti JC,Jr,Kane CJ,Terris MK,Aronson WJ,Amling CL,Freedland SJ. Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score? J Urol 2006; 176: 24538 discussion 58.
  • 30
    Greene KL,Elkin EP,Karapetian A,Duchane J,Carroll PR,Kane CJ. Prostate biopsy tumor extent but not location predicts recurrence after radical prostatectomy: results from CaPSURE. J Urol 2006; 175: 1259, discussion 29.
  • 31
    Yang XJ,Lecksell K,Potter SR,Epstein JI. Significance of small foci of Gleason score 7 or greater prostate cancer on needle biopsy. Urology 1999; 54: 52832.
  • 32
    Gunia S,Albrecht K,Koch S,Herrmann T,Ecke T,Loy V,Linke J,Siegsmund M,May M. Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability. World J Urol 2008; 26: 24350.
  • 33
    Laitinen S,Martikainen PM,Tolonen T,Isola J,Tammela TL,Visakorpi T. EZH2, Ki-67 and. MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer 2008; 122: 595602.
  • 34
    Rajinikanth A,Manoharan M,Soloway CT,Civantos FJ,Soloway MS. Trends in Gleason Score: concordance between biopsy and prostatectomy over 15 Years. Urology 2008; 72: 17782.
  • 35
    Vis AN,van Rhijn BW,Noordzij MA,Schroder FH,van der Kwast TH. Value of tissue markers p27(kip1), MIB-1, and. CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer. J Pathol 2002; 197: 14854.
  • 36
    Ojea Calvo A,Mosteiro Cervino MJ,Dominguez Freire F,Alonso Rodrigo A,Rodriguez Iglesias B,Benavente Delgado J,Barros Rodriguez JM,Gonzalez Pineiro A. [Prognostic factors of prostate cancer: usefulness of Ki-67 expression in preoperative biopsies]. Arch Esp Urol 2004; 57: 80516.
  • 37
    Vis AN,Noordzij MA,Fitoz K,Wildhagen MF,Schroder FH,van der Kwast TH. Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol 2000; 164: 215661.
  • 38
    Bettencourt MC,Bauer JJ,Sesterhenn IA,Mostofi FK,McLeod DG,Moul JW. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 1996; 156: 10648.
  • 39
    Cowen D,Troncoso P,Khoo VS,Zagars GK,von Eschenbach AC,Meistrich ML,Pollack A. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clin Cancer Res 2002; 8: 114854.
  • 40
    Halvorsen OJ,Haukaas S,Hoisaeter PA,Akslen LA. Maximum Ki-67 staining in prostate cancer provides independent prognostic information after radical prostatectomy. Anticancer Res 2001; 21: 40716.
  • 41
    Keshgegian AA,Johnston E,Cnaan A. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol 1998; 110: 4439.
  • 42
    Pollack A,DeSilvio M,Khor LY,Li R,Al-Saleem TI,Hammond ME,Venkatesan V,Lawton CA,Roach M,III,Shipley WU,Hanks GE,Sandler HM. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: radiation therapy oncology group trial 92-02. J Clin Oncol 2004; 22: 213340.
  • 43
    Khoo VS,Pollack A,Cowen D,Joon DL,Patel N,Terry NH,Zagars GK,von Eschenbach AC,Meistrich ML,Troncoso P. Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy. Prostate 1999; 41: 16672.
  • 44
    Dudderidge TJ,McCracken SR,Loddo M,Fanshawe TR,Kelly JD,Neal DE,Leung HY,Williams GH,Stoeber K. Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer. Br J Cancer 2007; 96: 138493.
  • 45
    Harnden P,Naylor B,Shelley MD,Clements H,Coles B,Mason MD. The clinical management of patients with a small volume of prostatic cancer on biopsy: what are the risks of progression?. A systematic review and meta-analysis. Cancer 2008; 112: 97181.
  • 46
    Jhavar S,Bartlett J,Kovacs G,Corbishley C,Dearnaley D,Eeles R,Khoo V,Huddart R,Horwich A,Thompson A,Norman A,Brewer D, et al. Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance. Prostate Cancer Prostatic Dis (in press).
  • 47
    Quinn DI,Henshall SM,Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer 2005; 41: 85887.
  • 48
    Zellweger T,Ninck C,Bloch M,Mirlacher M,Koivisto PA,Helin HJ,Mihatsch MJ,Gasser TC,Bubendorf L. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 2005; 113: 61928.
  • 49
    Yoshino T,Shiina H,Urakami S,Kikuno N,Yoneda T,Shigeno K,Igawa M. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res 2006; 12: 611624.
  • 50
    Khor LY,Moughan J,Al-Saleem T,Hammond EH,Venkatesan V,Rosenthal SA,Ritter MA,Sandler HM,Hanks GE,Shipley WU,Pollack A. Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02. Clin Cancer Res 2007; 13: 358590.
  • 51
    Tolcher AW,Chi K,Kuhn J,Gleave M,Patnaik A,Takimoto C,Schwartz G,Thompson I,Berg K,D'Aloisio S,Murray N,Frankel SR, et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005; 11: 385461.